• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

uniQure NV (QURE)

Ordinary Shares
Sell: $58.60|Buy: $59.00|Change: 1.99 (-3.32%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Address

Paasheuvelweg 25a
Amsterdam
NLD
1105 BP

Telephone

+1 339 9707536

Website

https://www.uniqure.com

Sector 

Healthcare

Forecast key dates

NameKey Date
uniQure NV Second Quarter Earnings Conference Call for 20262026-07-29T08:30:00
uniQure NV Second Quarter Earnings Results for 20262026-07-29T00:00:00
uniQure NV Annual General Meeting for 20262026-06-11T09:00:00
uniQure NV First Quarter Earnings Conference Call for 20262026-05-08T08:30:00
uniQure NV First Quarter Earnings Results for 20262026-05-08T00:00:00
uniQure NV Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
uniQure NV Annual Report for 20252026-02-27T00:00:00
uniQure NV Third Quarter Earnings Results for 20252025-11-05T00:00:00

Previous key dates

NameKey Date
uniQure Topline Pivotal Results for AMT-130 in Huntington’s Disease conference call 20252025-09-24T08:30:00
uniQure NV Second Quarter Earnings Conference Call for 20252025-07-29T08:30:00
uniQure NV Second Quarter Earnings Result for 20252025-07-29T00:00:00
uniQure NV Annual General Meeting for 20252025-06-11T09:00:00
uniQure NV First Quarter Earnings Conference Call for 20252025-05-09T08:30:00
uniQure NV First Quarter Earnings Result for 20252025-05-09T00:00:00
uniQure NV Fourth Quarter Earnings Results for 20242025-02-27T00:00:00
uniQure NV Annual Report for 20242025-02-27T00:00:00
Regulatory Update for AMT-1302024-12-10T08:30:00
uniQure NV Third Quarter Earnings Results for 20242024-11-05T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.